Changing treatment changing prognosis of mutations
Journal article
Vyas P., (2023), Blood, 142, 1583 - 1585
A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.
Journal article
Turkalj S. et al, (2023), STAR Protoc, 4
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Journal article
Daver NG. et al, (2023), J Clin Oncol
Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia
Preprint
Silveira DRA. et al, (2023)
Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.
Journal article
Freeman SD. et al, (2023), Blood
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Dataset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
An Overview of Targeted Therapies in Acute Myeloid Leukemia
Journal article
Turkalj S. et al, (2023), HemaSphere, 7
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Dataset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.
Journal article
Josa-Culleré L. et al, (2023), Eur J Med Chem, 258
GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells
Journal article
Turkalj S. et al, (2023), Cell Stem Cell, 30, 722 - 740.e11
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Journal article
Lachowiez CA. et al, (2023), Blood Cancer Discov